MedTrace Logo

Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP)

NCT04418375 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2024-05-03

No results posted yet for this study

Summary

The objective of the COVID-HOP study is to identify biological and non-biological markers associated to: a positive or negative serology anti SRAS-Cov-2; a positive serology and having presented symptoms or, on the contrary, not having had symptoms; the persistence of immunity or the loss of this immunity over time; the protective nature of the presence of anti SRAS-Cov-2 antibodies.

To answer these questions, a biological collection (serum, plasma, DNA, RNA, mono-nucleated cells and urine) and a collection of detailed clinical data during the serological screening for SARS-CoV-2 of hospital agents (medical and non-medical staff) of the Assistance Publique Hôpitaux de Paris (Paris, France) will be carried out. 4000 professionals in 5 hospitals will be included. As part of the research, the anti SRAS-CoV-2 serology will be monitored 6 months and 12 months after the initial serology. Numerous studies will be carried out from this biological collection and from the database to answer the primary and secondary endpoints.

Conditions

Sponsors & Collaborators

  • Fondation Université de Paris

    collaborator UNKNOWN

  • Fondation Hôpitaux de Paris-Hôpitaux de France

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Nathalie Dr DEMORY, PhD · AP-HP, Hôpital Européen Georges Pompidou, Paris

  • Solen Dr KERNEIS, PhD · AP-HP, Hôpital Cochin, Paris

  • Martine Dr LOUET, PhD · AP-HP, Hôpital la Pitié Salpêtrière, Paris

  • Bénédicte Dr SAWICKI, PhD · AP-HP, Hôpital Bichat, Paris

  • Véronique Dr MAHE, PhD · AP-HP, Hôpital Lariboisière, Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2022-10-08
Completion
2022-10-08

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04418375 on ClinicalTrials.gov